Richard Marais - Selected Publications#

180 total publications; h-index = 61 (as reported by Thomson Reuters Web of Science)

1. Girotti MR, Lopes F, Preece N, Niculescu-Duvaz D, Zambon A, Davies L, Whittaker S, Saturno G, Viros A, Pedersen M, Suijkerbuijk BM, Menard D, McLeary R, Johnson L, Fish L, Ejiama S, Sanchez-Laorden B, Hohloch J, Carragher N, Macleod K, Ashton G, Marusiak AA, Fusi A, Brognard J, Frame M, Lorigan P, Marais R, Springer C. (2015) Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma. Cancer Cell, 27(1):85-96. [1 citation]

2. Viros A, Sanchez-Laorden B, Pedersen M, Furney SJ, Rae J, Hogan K, Ejiama S, Girotti MR, Cook M, Dhomen N and Marais R (2014). Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53. Nature, 511(7510):478-82. [11 citations]

3. Sanchez-Laorden B, Viros A, Girotti MR, Pedersen M, Saturno, G, Zambon A, Niculescu-Duvaz D, Turajlic S, Hayes A, Gore M, Larkin J, Lorigan P, Cook M, Springer C and Marais R (2014). BRAF inhibitors induce metastasis in RAS-mutant and inhibitor-resistant melanoma cells through MEK/ERK pathway reactivation. Science Signaling, 7(318), ra30. [11 citations]

4. Girotti MR, Pedersen M, Sanchez-Laorden B, Viros A, Turajlic S, Niculescu-Duvaz D, Zambon A, Sinclair J, Hayes A, Gore M, Lorigan P, Springer C, Larkin J, Jorgensen C, Marais R (2013). Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discovery, 3: 158-167. [56 citations]

5. Furney SJ, Pedersen M, Gentien D, Dumont AG, Rapinat A, Desjardins L, Turajlic S, Piperno Neumann S, de la Grange P, Roman-Roman S, Stern M.-H., and Marais R (2013). SF3B1 mutations are associated with alternative splicing in uveal melanoma. Cancer Discovery, 3(10):1122-9. [22 citations]

6. Turajlic S, Furney SJ, Lambros MB, Mitsopoulos C, Kozarewa I, Geyer FC, MacKay A, Hakas J, Zvelebil M, Lord C, Ashworth A, Thomas M, Stamp G, Larkin J, Reis-Filho JS and Marais R (2012). Whole genome sequencing of matched primary and metastatic acral melanomas. Genome Research, 22: 196-207. [46 citations]

7. Su F, Viros A, Milagre C, Trunzer K, Bollag C, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT, Chapman PB, Jung Kim M, Hayward F, Martin M, Yang H, Wang Q, Hilton H, Hang JS, Noe J, Lambros M, Geyer F, Dhomen N, Niculescu-Duvaz I, Zambon A, Niculescu-Duvaz D, Preece N, Robert L, Otte NJ, Mok S, Kee D, Ma Y, Zhang C, Habets G, Burton EA, Wong B, Nguyen H, Kockx M, Andries L, Lestini B, Nolop KB, Lee RJ, Joe AK, Troy JL, Gonzalez F, Hutson TE, Puzanov I, Chmielowski B, Springer CJ, McArthur GA, Sosman JA, Lo RS, Ribas A, Marais R (2012). RAS mutations in cutaneous squamous cell carcinomas with BRAF inhibitors. The New England Journal of Medicine, 366: 207-215. [329 citations]

8. Arozarena I, Sanchez-Laorden B, Packer L, Hidalgo-Carcedo C, Hayward R, Viros A, Sahai E and Marais R (2011). Oncogenic BRAF induces melanoma cell invasion by down-regulating the cGMP-specific phosphodiesterase PDE5A. Cancer Cell, 19: 45-57. [62 citations]

9. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, Hussain J, Reis Filho JS, Springer CJ, Pritchard C and Marais R (2010). Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell, 140: 209-221. [554 citations]

10. Dhomen N, Reis-Filho JS, Da Rocha Dias S, Hayward R, Savage K, Delmas V, Larue L, Pritchard C and Marais R (2009). Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell, 15: 294-303. [216 citations]